Litigation

Recent Posts

William A. Ruskin: Ex Parte Communication With Plaintiff's Prescribing Physician
Posted on 21 Dec 2012 by William A. Ruskin

By William A. Ruskin In product liability litigation, a single tactical advantage may determine whether the case is won or lost. Often, being able to anticipate an issue before it arises and addressing it in the Case Management Order may be critical... Read More

Tags: Lela Hollabaugh , In Re: Yasmin And Yaz (Drospirenone) Marketing , Drug & Medical Device , drug product liability , ex parte communication , pharmaceutical product liability , William A. Ruskin , pharmaceutical mass tort , Litigation , Sales Practices and Products Liability Litigation , Vioxx Litigation , MDL

Yasmin, Yaz Gallbladder Cases Settled For $24 Million By Bayer; Payouts Are $2,000-$3,000
Posted on 18 Mar 2013 by Tom Moylan

EAST ST. LOUIS, Ill. — (Mealey’s) Bayer HealthCare Pharmaceuticals Inc. will pay $24 million to resolve claims of plaintiffs who allege that they developed gallbladder disease or underwent gallbladder surgery as a result of using Yasmin or... Read More

Tags: gallbladder disease , In Re: Yasmin and Yaz [Drospirenone] Marketing , drospirenone , Bayer HealthCare Pharmaceuticals , Litigation , multidistrict litigation , Yaz , Gallbladder Resolution Program , Settlement , birth control pills , Yasmin , Sales Practices and Products Liability Litigation , drugs and medical devices

Toyota Agrees To Fund Settlement Of Unintended Acceleration Cases Worth Up To $1.4 Billion
Posted on 28 Dec 2012 by LexisNexis Litigation Resource Community Staff

Attorney representing Toyota owners calls settlement "extraordinarily hard-fought, exceptionally far-reaching" LOS ANGELES - The attorneys representing Toyota owners who claim that their vehicles are prone to sudden, unexplained acceleration... Read More

Tags: Toyota , Hagens Berman , Litigation , In Re: Toyota Motor Corp. Unintended Acceleration Marketing , Settlement , Sales Practices and Products Liability Litigation , unexplained acceleration

3rd Circuit: Humana Can Sue GSK For Reimbursement For Avandia-Related Expenses
Posted on 29 Jun 2012 by Tom Moylan

PHILADELPHIA - (Mealey's) Medicare Advantage provider Humana Medical Plan Inc. is allowed under Medicare law to seek reimbursement from GlaxoSmithKline PLC (GSK) for the costs of treating insurance customers who were injured by GSK's Avandia diabetes... Read More

Tags: diabetes drug , Third Circuit , Medicare , In Re: Avandia Marketing , Humana Insurance Co. , class action , managed care , Litigation , GSK , GlaxoSmithKline , Medicare Secondary Payer Act , Sales Practices and Products Liability Litigation , Humana Medical Plan , Avandia , Medicare Advantage

Pfizer Ordered To Pay $47.3M To Health Insurer In Neurontin RICO Trial
Posted on 26 Mar 2010 by Tom Moylan

BOSTON — (Mealey’s) A Massachusetts federal jury on March 25 awarded $47.3 million to the Kaiser Foundation after finding that Pfizer Inc. engaged in racketeering and unfair competition through its off-label marketing of Neurontin ( In Re... Read More

Tags: Neurontin (In Re: Neurontin Marketing , RICO , unfair competition , Pfizer Inc. , Racketeer Influenced and Corrupt Organizations Act , racketeering , Kaiser Foundation Health Plan Inc. , Litigation , lawsuit , Sales Practices and Products Liability Litigation , Guardian Life Insurance Company of America v. Pfizer Inc. , Kaiser Foundation , Kaiser Foundation Hospital